Insider Transactions in Q1 2024 at Generation Bio Co. (GBIO)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 29
2024
|
Douglas Kerr CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,476
-0.38%
|
$1,476
$1.9 P/Share
|
|
Jan 29
2024
|
Douglas Kerr CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,021
+1.28%
|
-
|
|
Jan 29
2024
|
Tracy Zimmermann CHIEF DEVELOPMENT OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,476
-2.91%
|
$1,476
$1.9 P/Share
|
|
Jan 29
2024
|
Tracy Zimmermann CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,021
+9.02%
|
-
|
|
Jan 15
2024
|
Antoinette Paone CHIEF OPERATING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
3,637
-14.59%
|
$3,637
$1.91 P/Share
|
|
Jan 15
2024
|
Antoinette Paone CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,492
+29.63%
|
-
|
|
Jan 15
2024
|
Phillip Samayoa CHIEF STRATEGY OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
3,020
-1.34%
|
$3,020
$1.91 P/Share
|
|
Jan 15
2024
|
Phillip Samayoa CHIEF STRATEGY OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
8,712
+3.71%
|
-
|
|
Jan 15
2024
|
Geoff Mcdonough PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
15,431
-0.58%
|
$15,431
$1.91 P/Share
|
|
Jan 15
2024
|
Geoff Mcdonough PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
44,531
+1.66%
|
-
|
|
Jan 15
2024
|
Matthew Norkunas CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
5,478
-3.7%
|
$5,478
$1.91 P/Share
|
|
Jan 15
2024
|
Matthew Norkunas CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
15,805
+9.42%
|
-
|
|
Jan 15
2024
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
4,897
-1.0%
|
$4,897
$1.91 P/Share
|
|
Jan 15
2024
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
14,131
+2.81%
|
-
|
|
Jan 15
2024
|
Douglas Kerr CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
4,897
-0.64%
|
$4,897
$1.91 P/Share
|
|
Jan 15
2024
|
Douglas Kerr CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
14,131
+1.81%
|
-
|
|
Jan 15
2024
|
Tracy Zimmermann CHIEF DEVELOPMENT OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
4,897
-5.36%
|
$4,897
$1.91 P/Share
|
|
Jan 15
2024
|
Tracy Zimmermann CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
14,131
+13.38%
|
-
|
|
Jan 02
2024
|
Phillip Samayoa CHIEF STRATEGY OFFICER |
SELL
Open market or private sale
|
Direct |
2,445
-2.23%
|
$2,445
$1.62 P/Share
|
|
Jan 02
2024
|
Antoinette Paone CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
2,445
-29.55%
|
$2,445
$1.62 P/Share
|